Clinical trials: Tace
HCC
Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC
The goal of this Interventional Study is to compare the efficacy profile and safety of three treatments in patients with HCC nodule. Patients will be randomly divided in three arms: 1. Occlusafe assisted MWA+ DEB-TACE 2.
- Trial name
- SEASON-HCC (NCT05592171)
- Testing
- Microwave ablation + Occlusafe + DEB-TACE, Microwave ablation + Occlusafe, Microwave ablation + DEB-TACE
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Pisa
Hepatocellular Carcinoma (HCC)
TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma
This study investigates the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with the immune agent nivolumab compared to TACE alone for treating hepatocellular carcinoma (HCC).
- Trial name
- NCT07053202
- Testing
- Nivolumab, Transarterial Chemoembolization (TACE)
- Where
- China
- Volunteers
- 140 people
- Sponsor
- The First Hospital of Hebei Medical University
Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Preoperative Transarterial Chemoembolization for Resectable HCC With Portal Venous Invasion
Whether preoperative transarterial chemoembolization can prolong survival for the resectable hepatocellular carcinoma remains controversial, particularly in patients with portal vein tumor thrombi.
- Trial name
- NCT01952353
- Testing
- Preoprative TACE, Liver resection plus Thrombectomy
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Hepatocellular
Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma
The purpose of this study is to determine whether compared with arsenic trioxide TACE alone, arsenic trioxide TACE and intravenous administration could further prolong the overall survival.
- Trial name
- ACTION (NCT01861912)
- Testing
- Arsenic trioxide TACE, Arsenic trioxide intravenous infusion, lipiodol
- Volunteers
- 258 people
- Sponsor
- Guangdong Provincial People's Hospital
Hepatocellular Carcinoma, Transarterial Chemoembolization
TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial
Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world. Hepatic resection or liver transplantation is the radical method to cure the disease.
- Trial name
- Thalen (NCT04531228)
- Testing
- TACE-HAIC plus lenvatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Yunfei Yuan
Clinically Significant Portal Hypertension
The Effect of Sorafenib on Portal Pressure
Sorafenib is approved by the US FDA for the treatment of unresectable (can not operate) liver cancer and for renal cell carcinoma.
- Trial name
- NCT01714609
- Testing
- Sorafenib
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Yale University
Hepatocellular Carcinoma
A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection
The aim of this study is to analyze the therapeutic effect of adjuvant TACE after resection.Patients receiving curative resection (R0) were randomized to postoperative TACE group and no TACE group.
- Trial name
- NCT00820053
- Testing
- epirubicin and lipiodol
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Liver Cancer
Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients With Hepatocellular Carcinoma
To evaluate local tumor control and survival rate after repeated transarterial chemoembolization(TACE) using three different protocols in hepatocellular carcinoma (HCC) patients.
- Trial name
- NCT02038296
- Testing
- transarterial chemoembolization
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Guangdong Provincial People's Hospital
Hepatocellular Carcinoma
DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma
Transarterial chemoembolization (TACE) based on drug-eluting beads (DEB-TACE) is widely used for unresectable hepatocellular carcinoma (HCC). However, the long-term survival is still low after DEB-TACE treatment.
- Trial name
- NCT04229355
- Testing
- DEB-TACE plus Sorafenib, DEB-TACE plus Lenvatinib, DEB-TACE plus PD-1 inhibitor
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma
Transarterial Ethanol Ablation (TEA) Versus Transcatheter Arterial Chemoembolisation (TACE) for Hepatocellular Carcinoma
The current randomized controlled trial comparing LEM and TACE aims to evaluate the safety and efficacy of LEM as compared to TACE for treating patients with unresectable HCC.
- Trial name
- NCT00467974
- Testing
- TEA with LEM, TACE
- Where
- 3 sites in Hong Kong
- Volunteers
- 98 people
- Sponsor
- Chinese University of Hong Kong
Carcinoma, Hepatocellular
TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma
It is a prospective and multi-center clinical research in China to compare the efficacy, safety and related impact factors between TACE alone and TACE combined with synchronous multi-point MWA/RFA for large and huge liver cancer.
- Trial name
- NCT02630108
- Testing
- Thermal Ablation, EADM, Ultra-fluid lipiodol
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Shanghai Zhongshan Hospital
Unresectable Colorectal Liver Metastasis
Transarterial Chemoembolization by Hepasphere Microspheres for the Treatment of Unresectable Colorectal Liver Metastasis
Colorectal cancer is the third most frequently diagnosed cancer and the third leading cause of cancer related deaths in Taiwan. Of the 10,248 new colorectal patients diagnosed each year approximately 60% will develop liver…
- Trial name
- NCT03264716
- Testing
- HepaSphere TACE (transarterial chemoembolization)
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies in patients with advanced-stage…
- Trial name
- CHANCE2201 (NCT05332821)
- Testing
- PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE
- Where
- 2 sites in China
- Volunteers
- 1,244 people
- Sponsor
- Zhongda Hospital
Cancer
Effectiveness of Knowledge by Video and Handbook of Liver Cancer Patients With First Trans-arterial Chemoembolization
Objective: To compare the effectiveness between Video and Handbook on providing knowledge of TACE. Study Design: A prospective, randomized, controlled trial.
- Trial name
- NCT02768428
- Testing
- Video-Audio Media
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- Chulabhorn Hospital
Hepatocellular Carcinoma
Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma
TACE is considered the standard treatment for unresectable HCC and is widely used as a palliative treatment. However there is no consensus of the protocol of TACE.One of the variation is does the stability of the suspension by…
- Trial name
- NCT01259414
- Testing
- Solvent with specific gravity less than lipiodol, Solvent with specific gravity equivalent to lipiodol
- Where
- China
- Volunteers
- 812 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma Non-resectable
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
This study is conducted to evaluate the efficacy and safety of lenvatinib plus iodine-125 seed brachytherapy (Len-I) compared with lenvatinib (Len) alone for patients with hepatocellular carcinoma (HCC) refractory to…
- Trial name
- NCT05608213
- Testing
- Lenvatinib Plus I-125 Seed Brachytherapy, Lenvatinib
- Where
- China
- Volunteers
- 187 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma (HCC)
Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without TACE for Advanced HCC With Vascular Invasions
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma with…
- Trial name
- NCT06881446
- Where
- China
- Volunteers
- 2,651 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)
Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)
A Single center, Open, Randomized Controlled Trial Evaluating the Safety and Efficacy of GSMs-TACE Combined with Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) with Type III Portal Vein Tumor Thrombus…
- Trial name
- NCT04619342
- Testing
- GSMs-TACE, Surgical Resection
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Hepatic Carcinoma
Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.
Efficacy and Safety of Locoregional treatments Combined With PD-1 Inhibitor in Patients With Unresectable Hepatocellular Carcinoma.
- Trial name
- NCT04220944
- Testing
- Sintilimab, Microwave Ablation, TACE
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Zhongshan Hospital
Enhanced Recovery After Surgery, Multimodal Analgesia
Enhanced Recovery After Surgery-Based Multimodal Preemptive Analgesia for Perioperative Management in Transarterial Chemoembolization of Intermediate-to-Advanced Hepatocellular Carcinoma
To evaluate the effectiveness of the combination of hydrochloride hydromorphone and flurbiprofen ester for post-TACE intravenous patient-controlled intravenous analgesia (PCIA).
- Conditions
- Enhanced Recovery After Surgery, Multimodal Analgesia, Real-world Study, Transarterial Chemoembolization
- Trial name
- NCT07315022
- Testing
- hydrochloride hydromorphone + flurbiprofen axetil, conventional analgesia
- Where
- China
- Volunteers
- 129 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University